Hydroxyprogesterone - AMAG Pharmaceuticals
Alternative Names: 17 a-Hydroxyprogesterone Caproate; 17 α-hydroxyprogesterone caproate; 17-AHPC; 17-HPC; 17-OHPC; 17P; Gestiva; Hydroxyprogesterone caproate; Hydroxyprogesterone caproate injection; Hydroxyprogesterone long-acting; Makena; Makena QuickShot Auto Injector; Makena SQLatest Information Update: 12 Apr 2023
Price :
$50 *
At a glance
- Originator Cytyc Prenatal Products
- Developer AMAG Pharmaceuticals
- Class Pregnenediones; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Preterm labour
Most Recent Events
- 07 Mar 2023 Withdrawn for Preterm labour (Prevention) in USA (IM)
- 07 Mar 2023 Withdrawn for Preterm labour (Prevention) in USA (SC)
- 19 Oct 2022 The Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC) voted to recommend withdrawal of approval of Hydroxyprogesterone injection (Makena®) in USA